XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Expenses        
Research and development $ 2,535 $ 1,928 $ 5,976 $ 4,804
General and administrative expenses 2,224 2,241 6,523 6,288
Loss from operations (4,759) (4,169) (12,499) (11,092)
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone (498) (428)
Share of loss in associate accounted for using equity method (152) (261) (268) (363)
Change in fair value of warrant liability 8 342 33 726
Foreign exchange transaction gain (loss) 50 (60)
Depreciation expense (1) (1)
Interest income 50 115
Interest expense (1) (9) (42)
Loss before provision for income taxes (5,302) (4,089) (13,117) (10,771)
Income tax (expense) benefit (2,199) (117) 2,906 465
Net loss (7,501) (4,206) (10,211) (10,306)
Other comprehensive income (loss)        
Net unrealized loss on investments (4,017) (4,017)
Total comprehensive loss for period (11,518) (4,206) (14,228) (10,306)
Net loss attributable to:        
Owners of the Company (7,485) (3,512) (10,163) (9,553)
Non-controlling interest (16) (694) (48) (753)
Comprehensive loss attributable to:        
Owners of the Company (11,502) (3,512) (14,180) (9,553)
Non-controlling interest (16) (694) (48) (753)
Total comprehensive loss for period $ (11,518) $ (4,206) $ (14,228) $ (10,306)
Loss per share        
Basic and diluted $ (0.44) $ (0.26) $ (0.65) $ (0.74)
Weighted average shares outstanding        
Basic and diluted $ 17,039 $ 13,344 $ 15,719 $ 12,966